A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...

A decision is expected in the fourth quarter of 2025.

Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for an investigational once-daily, 25 mg oral formulation of Wegovy® ...

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

Research revealed that medications widely used for diabetes and obesity may offer significant benefits for patients with ...

A new study reveals that semaglutide, a common diabetes medication, may effectively treat fatty liver disease, offering hope ...

CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy ...